Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bacteriophage therapeutics - BiomX

Next Previous
Drug Profile

Bacteriophage therapeutics - BiomX

Alternative Names: PhageBank based therapeutics - BiomX; PhageBankTM; PhageBank®; WRAIR-PAM-CF1; WRAIR_PAM-CF1

Latest Information Update: 02 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Naval Medical Research Center; Walter Reed Army Institute of Research
  • Developer BiomX; National Institute of Allergy and Infectious Diseases
  • Class Anti-infectives; Antibacterials; Bacteriophages; Urinary anti-infective agents
  • Mechanism of Action Bacterial growth inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone and joint infections
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cystic fibrosis-associated respiratory tract infections; Osteomyelitis; Urinary tract infections
  • No development reported Bacterial infections; Bone and joint infections

Most Recent Events

  • 25 Apr 2025 National Institute of Allergy and Infectious Diseases completes a phase-I/II trial in Cystic fibrosis-associated respiratory tract infections in the US (IV, Infusion) (NCT05453578)
  • 28 Mar 2025 No recent reports of development identified for preclinical development in Bone-and-joint-infections in USA (Parenteral)
  • 01 Apr 2024 Adaptive Phage Therapeutics has been acquired and merged into BiomX

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top